CMS on deep-brain stimulation
This article was originally published in The Gray Sheet
Executive Summary
National coverage determination for Parkinson's disease treatment expected by year-end, the agency states Nov. 4. The Medicare Coverage Advisory Committee executive committee previously voted for an NCD for bilateral deep-brain stimulation in a well-defined set of Parkinson's patients (1"The Gray Sheet" Sept. 30, 2002, p. 11)...
You may also be interested in...
“Substantial” Device Effectiveness Proposed As Coverage Decision Category
CMS will allow the Medicare Coverage Advisory Committee to designate a new effectiveness category for devices showing a "substantial clinical benefit" over existing technologies, Acting Chief Clinical Officer Sean Tunis indicated Sept. 25
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.